CANADA LIFE ASSURANCE Co Decreases Stake in REGENXBIO Inc. (NASDAQ:RGNX)

CANADA LIFE ASSURANCE Co reduced its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 84.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,649 shares of the biotechnology company's stock after selling 36,699 shares during the quarter. CANADA LIFE ASSURANCE Co's holdings in REGENXBIO were worth $51,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in RGNX. Jump Financial LLC lifted its position in shares of REGENXBIO by 144.9% during the 4th quarter. Jump Financial LLC now owns 192,708 shares of the biotechnology company's stock valued at $1,490,000 after acquiring an additional 114,005 shares during the period. Walleye Capital LLC bought a new position in shares of REGENXBIO during the 4th quarter worth about $681,000. XTX Topco Ltd grew its stake in shares of REGENXBIO by 720.5% in the 4th quarter. XTX Topco Ltd now owns 108,120 shares of the biotechnology company's stock valued at $836,000 after buying an additional 94,943 shares during the period. Barclays PLC grew its stake in shares of REGENXBIO by 9.5% in the 4th quarter. Barclays PLC now owns 127,065 shares of the biotechnology company's stock valued at $982,000 after buying an additional 11,041 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in REGENXBIO in the 4th quarter valued at about $568,000. 88.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RGNX shares. Raymond James began coverage on REGENXBIO in a report on Friday, February 7th. They set an "outperform" rating and a $27.00 price objective for the company. The Goldman Sachs Group dropped their price objective on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Royal Bank of Canada reissued an "outperform" rating and set a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. Morgan Stanley raised their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, March 14th. Finally, Chardan Capital reissued a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a report on Thursday, March 20th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Price Performance

Shares of NASDAQ RGNX traded up $0.57 during midday trading on Friday, reaching $10.40. The company's stock had a trading volume of 1,015,830 shares, compared to its average volume of 822,267. The stock has a market capitalization of $521.22 million, a P/E ratio of -2.07 and a beta of 1.11. The firm has a 50 day moving average price of $7.16 and a 200-day moving average price of $8.09. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $17.52.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.26. The firm had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. On average, equities analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.